Laurent Levy Explained

Laurent Levy
Birth Date:1971
Birth Place:Montreuil, France
Education:Pierre and Marie Curie University, now Paris-Sorbonne University (BS, MS)
SUNY Buffalo (PhD)
Occupation:CEO of Nanobiotix

Laurent Levy (born 1971) is a French physical chemist, inventor, and pioneer of nanotechnology and nanomedicine. He is the co-founder of the global biotechnology company Nanobiotix, and has served as chief executive officer (CEO) since its inception in March 2003.[1] [2] [3] [4] He also authored more than 35 international scientific publications and has applied for several patents.[5]

Early life and education

Laurent Levy was born on the outskirts of northern-east Paris, France, in Montreuil.

After high school, Laurent went on to study biology at Pierre and Marie Curie University (Paris VI). He changed his area of study to biophysics then to physics and chemistry after two years, graduating with his bachelor's degree in 1994. He then earned his master's degree (DEA) in physics of condensed matter from UPVI-ESPCI.[6]

Laurent attended Paris VI and the CEA for doctoral studies in physical chemistry, specializing in nanomaterials. His doctoral thesis centered on quantum confinement as it relates to magnetic semiconductors.[7]

Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Prof. Paras N. Prasad at the Institute for Lasers, Photonics, and Biophotonics at SUNY Buffalo in the United States.[8] [9] [10]

Work

In 2003, Levy founded Nanobiotix to create a medical treatment using the techniques he developed at SUNY Buffalo. Nanobiotix would build on his work to develop what is now known as NBTXR3, a first-in-class “radioenhancer” designed to significantly increase the efficacy of radiation therapy without increasing negative side effects associated with radiation. In 2011, Nanobiotix treated its first patient using NBTXR3. In 2018 the results of a phase III clinical trial established that this new type of product could work in humans. In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall.[11] [12] [13] [14] In 2015 Levy joined the board of biotech startup Valbiotis, the first company to register a nutraceutical based on clinical findings. The company develops nutraceutical products for the prevention of diabetes in pre-diabetics. Levy helped take Valbiotis public in 2018.[15] [16]

In 2019, Levy co-founded the biotechnology company Curadigm as a spin-off from Nanobiotix. Curadigm's lead technology is a nanoprimer that affects liver function, reducing its ability to filter out drugs, making drug delivery more efficacious.[17] [18] [19]

European nanomedicine advocacy

As Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the European Union. To advocate for nanomedical development, Levy joined the European Technology Platform Nanomedicine (ETPN) in 2012 and was elected vice president.[20] [21] [22] Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies. Levy also helped to establish the ETPN's Nanomedicine Translation Hub, which advises SMEs, Startups, Academics and Inventors on how to bring their nanomedicine projects to the market.[23] [24]

Awards and recognition

External links

Patents

Publications

Notes and References

  1. Web site: Laurent Levy . The Pharma Letter . 2020-03-05. Web site: Interview: Laurent Levy – CEO, Nanobiotix, France . PharmaBoardroom . 2017-06-13 . . 2020-03-05.
  2. Web site: Interview with Laurent Levy, CEO of Nanobiotix - BioFIT 2020 . BioFIT 2020 . 2016-11-08 . . 2020-03-05.
  3. Web site: Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award . Applied Sciences from Technology Networks . 2013-04-04 . . 2020-03-05.
  4. Web site: The management . Nanobiotix . 2019-02-28 . . 2020-03-05.
  5. Web site: 2020-03-20. Levy, Laurent. 2020-06-17. The Wall Street Transcript. en-US.
  6. Levy . L. . Hochepied . J. F. . Pileni . M. P. . Control of the Size and Composition of Three Dimensionally Diluted Magnetic Semiconductor Clusters . The Journal of Physical Chemistry . American Chemical Society (ACS) . 100 . 47 . 1996 . 0022-3654 . 10.1021/jp960824w . 18322–18326 .
  7. Levy . L. . Feltin . N. . Ingert . D. . Pileni . M. P. . Three Dimensionally Diluted Magnetic Semiconductor Clusters Cd1-yMnyS with a Range of Sizes and Compositions: Dependence of Spectroscopic Properties on the Synthesis Mode . The Journal of Physical Chemistry B . American Chemical Society (ACS) . 101 . 45 . 1997 . 1520-6106 . 10.1021/jp970978r . 9153–9160 .
  8. Web site: The management . Nanobiotix . 2019-02-28 . . 2020-03-06.
  9. Web site: UB spinoff Nanobiotix looks to bring cancer treatment to market . University at Buffalo . 2014-05-23 . . 2020-03-06.
  10. Web site: Reuters Editorial . Officer Profile - Quotes . IN . 2020-03-05 . https://web.archive.org/web/20200323010553/https://in.reuters.com/finance/stocks/officer-profile/NANOB.PA/1779494 . dead . 2020-03-23 . 2020-03-06.
  11. Bonvalot . Sylvie . Rutkowski . Piotr L . Thariat . Juliette . Carrère . Sébastien . Ducassou . Anne . Sunyach . Marie-Pierre . Agoston . Peter . Hong . Angela . Mervoyer . Augustin . Rastrelli . Marco . Moreno . Victor . Li . Rubi K . Tiangco . Béatrice . Herraez . Antonio Casado . Gronchi . Alessandro . Mangel . László . Sy-Ortin . Teresa . Hohenberger . Peter . Baère . Thierry de . Cesne . Axel Le . Helfre . Sylvie . Saada-Bouzid . Esma . Borkowska . Aneta . Anghel . Rodica . Co . Ann . Gebhart . Michael . Kantor . Guy . Montero . Angel . Loong . Herbert H . Vergés . Ramona . Lapeire . Lore . Dema . Sorin . Kacso . Gabriel . Austen . Lyn . Moureau-Zabotto . Laurence . Servois . Vincent . Wardelmann . Eva . Terrier . Philippe . Lazar . Alexander J . Bovée . Judith V M G . Péchoux . Cécile Le . Papai . Zsusanna . NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial . The Lancet Oncology . 20 . 8 . 2019-08-01 . 1470-2045 . 31296491 . 10.1016/S1470-2045(19)30326-2 . 1148–1159 . free .
  12. Web site: Swift . Diana . Novel Radioenhancer Boosts RT Response in Sarcoma . MedPage Today . 2019-07-16 . 2020-03-05.
  13. Clinical Cancer Research. 2016-12-22 . 23 . 4 . 908–917 . 10.1158/1078-0432.CCR-16-1297 . 27998887 . First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas . Bonvalot . Sylvie . Le Pechoux . Cécile . De Baere . Thierry . Kantor . Guy . Buy . Xavier . Stoeckle . Eberhard . Terrier . Philippe . Sargos . Paul . Coindre . Jean Michel . Lassau . Nathalie . Ait Sarkouh . Rafik . Dimitriu . Mikaela . Borghi . Elsa . Levy . Laurent . Deutsch . Eric . Soria . Jean-Charles . free .
  14. Web site: Cynthia E. Keen. Potential benefits of adding radioenhancer nanoparticles to RT treatment for soft-tissue sarcoma . Applied Radiation Oncology . 2020-03-05.
  15. Web site: Research & Development Company . Valbiotis . 2018-07-31 . . 2020-03-05.
  16. Web site: VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes . BioSpace . 2019-07-03 . . 2020-03-05.
  17. Web site: Together to Reshape Healthcare Full Version . Curadigm . 2019-05-17 . . 2020-03-05.
  18. Web site: New Nanobiotix subsidiary to use 'nanoprimer' tech . The Pharma Letter . 2020-03-05.
  19. Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile - Scientific Reports . Scientific Reports . 19 March 2018 . 8 . 1 . 4797 . 10.1038/s41598-018-23140-9 . . Pottier . Agnès . Levy . Laurent . Bergere . Maxime . Mpambani . Francis . Berjaud . Céline . Paolini . Marion . Poul . Laurence . Meyre . Marie-Edith . Germain . Matthieu . 29556068 . 5859131 .
  20. Lévy . Laurent . Europe as leaders in nanomedicine: let's go for it! . Nanomedicine . Future Medicine Ltd . 9 . 4 . 2014 . 1743-5889 . 10.2217/nnm.14.14 . 389–391 . 24787438 .
  21. Eaton . Michael A.W. . Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry . Journal of Controlled Release . June 2012 . 164 . 3 . 370–371 . 10.1016/j.jconrel.2012.06.016 . 22721816 . 5 March 2020.
  22. Eaton . Mike . Improving Innovation in Nano-Healthcare Funding . Precision Nanomedicine . March 2018 . 1 . 10.29016/180108.1. free .
  23. Web site: HealthtechTAB . HealthtechTAB . 2019-10-11 . . 2020-03-05.
  24. Web site: ETPN . The Nanomedicine Translation Hub . . 2020-03-05.
  25. News: Nanotech company Nanobiotix earns Prix Galien Award for innovation . 5 March 2020 . Applied Radiation Oncology . Dec 17, 2019.
  26. Web site: Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award . Applied Sciences from Technology Networks . 2013-04-04 . . 2020-03-05.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Laurent Levy".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.